These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25535815)

  • 1. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
    Penot A; Preux PM; Le Guyader S; Collignon A; Herry A; Dufour V; Monnereau A; Woronoff AS; Troussard X; Pons E; Bordessoule D; Maynadié M
    Leuk Lymphoma; 2015 Jun; 56(6):1771-7. PubMed ID: 25535815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
    Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
    BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
    Hoffmann VS; Baccarani M; Hasford J; Castagnetti F; Di Raimondo F; Casado LF; Turkina A; Zackova D; Ossenkoppele G; Zaritskey A; Höglund M; Simonsson B; Indrak K; Sninska Z; Sacha T; Clark R; Bogdanovic A; Hellmann A; Griskevicius L; Schubert-Fritschle G; Sertic D; Guilhot J; Lejniece S; Zupan I; Burgstaller S; Koskenvesa P; Everaus H; Costeas P; Lindoerfer D; Rosti G; Saussele S; Hochhaus A; Hehlmann R
    Leukemia; 2017 Mar; 31(3):593-601. PubMed ID: 27568522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
    Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
    Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
    Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
    Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
    Eur J Haematol; 2016 Oct; 97(4):387-92. PubMed ID: 26833713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
    Rebora P; Czene K; Antolini L; Gambacorti Passerini C; Reilly M; Valsecchi MG
    Am J Epidemiol; 2010 Nov; 172(9):1028-33. PubMed ID: 20861143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.
    Lauseker M; Gerlach R; Tauscher M; Hasford J
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1441-7. PubMed ID: 27085527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rising prevalence of chronic myeloid leukemia in France.
    Delord M; Foulon S; Cayuela JM; Rousselot P; Bonastre J
    Leuk Res; 2018 Jun; 69():94-99. PubMed ID: 29734071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study].
    Kulikov SM; Vinogradova OIu; Chelysheva EIu; Tishchenko IA; Galaĭko MA; Lazareva OV; Senderova OM; Pepeliaeva VM; Meresiĭ SV; Luchinin AS; Ovsepian VA; Miliutina GI; Gavrilova LV; Avdeeva LB; Neverova AL; Turkina AG
    Ter Arkh; 2014; 86(7):24-30. PubMed ID: 25314774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
    Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
    Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Descriptive epidemiology of myeloid leukemia].
    Matsuo K; Ito H
    Nihon Rinsho; 2009 Oct; 67(10):1847-51. PubMed ID: 19860178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in leukemia incidence and survival in the United States (1973-1998).
    Xie Y; Davies SM; Xiang Y; Robison LL; Ross JA
    Cancer; 2003 May; 97(9):2229-35. PubMed ID: 12712476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
    Hoffmann VS; Baccarani M; Hasford J; Lindoerfer D; Burgstaller S; Sertic D; Costeas P; Mayer J; Indrak K; Everaus H; Koskenvesa P; Guilhot J; Schubert-Fritschle G; Castagnetti F; Di Raimondo F; Lejniece S; Griskevicius L; Thielen N; Sacha T; Hellmann A; Turkina AG; Zaritskey A; Bogdanovic A; Sninska Z; Zupan I; Steegmann JL; Simonsson B; Clark RE; Covelli A; Guidi G; Hehlmann R
    Leukemia; 2015 Jun; 29(6):1336-43. PubMed ID: 25783795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Sasaki K; Kantarjian HM; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda WG; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce SA; Jabbour EJ; Cortes JE
    Int J Hematol; 2019 May; 109(5):545-552. PubMed ID: 30830579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries.
    Polednak AP
    J Registry Manag; 2014; 41(2):77-84. PubMed ID: 25153013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.
    Chen Y; Wang H; Kantarjian H; Cortes J
    Leuk Lymphoma; 2013 Jul; 54(7):1411-7. PubMed ID: 23121646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.
    Gunnarsson N; Höglund M; Stenke L; Wållberg-Jonsson S; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Wadenvik H; Richter J; Själander A
    Leukemia; 2016 Jul; 30(7):1562-7. PubMed ID: 27080811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
    Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
    Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.